Ganesh (emory university) - mcsp - HIT to lead chemistry
Ended Awarded Last action
- Contract number
- 75N95022F00004
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,873,043
Award facts
- Contract value 100% obligated
- $2,873,042.91 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $1,524,143 | |
| Original award | $1,348,899 |
About this award
This is a federal contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke to Curia Global Inc., doing business as Amri, a leading global contract development and manufacturing organization (CDMO). The $2,873,042.91 contract is for the Medicinal Chemistry Support Program for Therapeutic Development, under which Curia will provide a range of chemistry, manufacturing, and controls development services, including hit-to-lead chemistry, absorption/distribution/metabolism/excretion testing, process chemistry, scale-up synthesis, good manufacturing practices production, and stability testing across therapeutic areas like neurology. This award does not have a set-aside designation. Curia has previously supported various NIH institutes and programs, leveraging its expertise in drug discovery, development, and manufacturing to assist federal research and development initiatives.
Quick answers
Who was awarded contract 75N95022F00004?
75N95022F00004 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on May 9, 2022.
How much is contract 75N95022F00004 worth?
The government has obligated $2,873,043 on 75N95022F00004.
Which agency awarded contract 75N95022F00004?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022F00004, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95022F00004 an order under another contract?
Yes. 75N95022F00004 is a delivery order under HHSN271201800001I, an indefinite delivery contract.
Was contract 75N95022F00004 competed?
The extent of competition for 75N95022F00004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award